Briefly, mutations in this domain cause abnormal increased autophosphorylation episodes that artificially activate the EGFR and cause the receptor to initiate signaling pathways through signal transducers within the tumor microenvironment (Figure 3). The gene discussed is EGFR; the disease is neoplasm.